JP2012176953A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012176953A5 JP2012176953A5 JP2012087648A JP2012087648A JP2012176953A5 JP 2012176953 A5 JP2012176953 A5 JP 2012176953A5 JP 2012087648 A JP2012087648 A JP 2012087648A JP 2012087648 A JP2012087648 A JP 2012087648A JP 2012176953 A5 JP2012176953 A5 JP 2012176953A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- human
- fragment
- kir2dl1
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 25
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 25
- 101001027081 Homo sapiens Killer cell immunoglobulin-like receptor 2DL1 Proteins 0.000 claims 17
- 102000047041 human KIR2DL1 Human genes 0.000 claims 13
- 101000945371 Homo sapiens Killer cell immunoglobulin-like receptor 2DL2 Proteins 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 5
- 101000945343 Homo sapiens Killer cell immunoglobulin-like receptor 2DS3 Proteins 0.000 claims 4
- 102100037363 Killer cell immunoglobulin-like receptor 2DL1 Human genes 0.000 claims 4
- 102100033599 Killer cell immunoglobulin-like receptor 2DL2 Human genes 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 102000058207 human KIR2DL2 Human genes 0.000 claims 3
- 101000945342 Homo sapiens Killer cell immunoglobulin-like receptor 2DS4 Proteins 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 2
- 102100033625 Killer cell immunoglobulin-like receptor 2DS3 Human genes 0.000 claims 2
- 102100033624 Killer cell immunoglobulin-like receptor 2DS4 Human genes 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 102000053035 human KIR2DS3 Human genes 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000002698 KIR Receptors Human genes 0.000 claims 1
- 108010043610 KIR Receptors Proteins 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48389403P | 2003-07-02 | 2003-07-02 | |
| US60/483,894 | 2003-07-02 | ||
| US54547104P | 2004-02-19 | 2004-02-19 | |
| US60/545,471 | 2004-02-19 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006515738A Division JP5015592B2 (ja) | 2003-07-02 | 2004-07-01 | Ｎｋ細胞活性を制御するための組成物及び方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015042824A Division JP6556465B2 (ja) | 2003-07-02 | 2015-03-04 | Ｎｋ細胞活性を制御するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012176953A JP2012176953A (ja) | 2012-09-13 |
| JP2012176953A5 true JP2012176953A5 (OSRAM) | 2013-04-18 |
| JP5826697B2 JP5826697B2 (ja) | 2015-12-02 |
Family
ID=33567703
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006515738A Expired - Lifetime JP5015592B2 (ja) | 2003-07-02 | 2004-07-01 | Ｎｋ細胞活性を制御するための組成物及び方法 |
| JP2006516606A Expired - Lifetime JP4871125B2 (ja) | 2003-07-02 | 2004-07-01 | Ｎｋ細胞活性を調節するための組成物および方法 |
| JP2012087648A Expired - Lifetime JP5826697B2 (ja) | 2003-07-02 | 2012-04-06 | Ｎｋ細胞活性を制御するための組成物及び方法 |
| JP2015042824A Expired - Lifetime JP6556465B2 (ja) | 2003-07-02 | 2015-03-04 | Ｎｋ細胞活性を制御するための組成物及び方法 |
| JP2018078329A Pending JP2018153185A (ja) | 2003-07-02 | 2018-04-16 | Ｎｋ細胞活性を制御するための組成物及び方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006515738A Expired - Lifetime JP5015592B2 (ja) | 2003-07-02 | 2004-07-01 | Ｎｋ細胞活性を制御するための組成物及び方法 |
| JP2006516606A Expired - Lifetime JP4871125B2 (ja) | 2003-07-02 | 2004-07-01 | Ｎｋ細胞活性を調節するための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015042824A Expired - Lifetime JP6556465B2 (ja) | 2003-07-02 | 2015-03-04 | Ｎｋ細胞活性を制御するための組成物及び方法 |
| JP2018078329A Pending JP2018153185A (ja) | 2003-07-02 | 2018-04-16 | Ｎｋ細胞活性を制御するための組成物及び方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US9902936B2 (OSRAM) |
| EP (3) | EP2289939B1 (OSRAM) |
| JP (5) | JP5015592B2 (OSRAM) |
| KR (5) | KR101444717B1 (OSRAM) |
| CN (2) | CN103588880B (OSRAM) |
| AT (1) | ATE490984T1 (OSRAM) |
| AU (2) | AU2004253770C1 (OSRAM) |
| BR (2) | BRPI0412138B8 (OSRAM) |
| CA (2) | CA2530272C (OSRAM) |
| CY (1) | CY1113394T1 (OSRAM) |
| DE (1) | DE602004030464D1 (OSRAM) |
| DK (2) | DK1639013T3 (OSRAM) |
| ES (2) | ES2393485T3 (OSRAM) |
| HR (1) | HRP20120845T1 (OSRAM) |
| IL (3) | IL172613A (OSRAM) |
| MX (1) | MXPA05013923A (OSRAM) |
| NO (4) | NO338818B1 (OSRAM) |
| PL (1) | PL1639013T3 (OSRAM) |
| PT (1) | PT1639013E (OSRAM) |
| RU (2) | RU2376315C2 (OSRAM) |
| WO (2) | WO2005003172A2 (OSRAM) |
Families Citing this family (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090191213A9 (en) * | 2003-07-02 | 2009-07-30 | Novo Nordisk A/S | Compositions and methods for regulating NK cell activity |
| CA2532547C (en) | 2003-07-24 | 2020-02-25 | Innate Pharma | Methods and compositions for increasing the efficiency of therapeutic antibodies using nk cell potentiating compounds |
| WO2005105849A1 (en) * | 2004-04-30 | 2005-11-10 | Innate Pharma | Compositions and methods for treating proliferative disorders such as nk-type ldgl |
| ES2360467T3 (es) * | 2004-07-01 | 2011-06-06 | Novo Nordisk A/S | Anticuerpos que se unen a receptores kir2dl1, -2, -3 pero no a kir2ds4 y su uso terapéutico. |
| CA2601417C (en) * | 2004-07-01 | 2018-10-30 | Novo Nordisk A/S | Human anti-kir antibodies |
| WO2006023148A2 (en) | 2004-07-10 | 2006-03-02 | Fox Chase Cancer Center | Genetically modified human natural killer cell lines |
| WO2006050270A2 (en) * | 2004-11-02 | 2006-05-11 | The Government Of The United States Of America As Represented By The Secretary Department Of Health & Human Services | Compositions and methods for treating hyperproliferative disorders |
| JP5855326B2 (ja) * | 2005-01-06 | 2016-02-09 | ノヴォ ノルディスク アー／エス | 抗ｋｉｒ組み合わせ治療および方法 |
| JP5154949B2 (ja) | 2005-01-06 | 2013-02-27 | ノヴォ ノルディスク アー／エス | ウイルス感染を治療するための組成物および方法 |
| EP1836225B1 (en) | 2005-01-06 | 2011-11-02 | Novo Nordisk A/S | Kir-binding agents and methods of use thereof |
| GT200600148A (es) * | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis | |
| EP2322557B1 (en) | 2005-10-14 | 2017-08-30 | Innate Pharma | Compositions and methods for treating proliferative disorders |
| EP2109460B1 (en) | 2007-01-11 | 2016-05-18 | Novo Nordisk A/S | Anti-kir antibodies, formulations, and uses thereof |
| US8709411B2 (en) | 2008-12-05 | 2014-04-29 | Novo Nordisk A/S | Combination therapy to enhance NK cell mediated cytotoxicity |
| WO2010076788A2 (en) * | 2008-12-29 | 2010-07-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection |
| US20120308986A1 (en) * | 2010-02-08 | 2012-12-06 | Biotherapy Institute Of Japan | Method for producing nk cell-enriched blood product |
| CN106963947A (zh) | 2010-11-22 | 2017-07-21 | 伊纳特医药股份有限公司 | Nk细胞调节治疗和用于治疗血液恶性疾病的方法 |
| AU2012260601B2 (en) | 2011-05-25 | 2018-02-01 | Innate Pharma, S.A. | Anti-KIR antibodies for the treatment of inflammatory disorders |
| EP2723362A1 (en) | 2011-06-21 | 2014-04-30 | Innate Pharma | NKp46-MEDIATED NK CELL TUNING |
| JO3370B1 (ar) * | 2011-11-10 | 2019-03-13 | Regeneron Pharma | طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 |
| CN103946236B (zh) * | 2011-11-23 | 2018-02-16 | 弗·哈夫曼-拉罗切有限公司 | 表达cd40l的哺乳动物细胞及其用途 |
| AU2013320360B2 (en) * | 2012-09-19 | 2018-06-14 | Innate Pharma | KIR3DL2 binding agents |
| SG10201702421TA (en) | 2012-10-02 | 2017-05-30 | Bristol Myers Squibb Co | Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer |
| WO2015069785A1 (en) | 2013-11-06 | 2015-05-14 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma |
| EP3187583B1 (en) * | 2014-08-29 | 2023-04-26 | National University Corporation Hokkaido University | Monoclonal antibody against kir2ds1 |
| ES2772307T3 (es) | 2014-10-28 | 2020-07-07 | Childrens Univ Hospital Tuebingen | Tratamiento de pacientes pediátricos con LLA-PCB con un anticuerpo anti-kir |
| PL3253865T3 (pl) | 2015-02-06 | 2022-10-10 | National University Of Singapore | Sposoby wzmacniania skuteczności terapeutycznych komórek odpornościowych |
| KR102740444B1 (ko) | 2015-04-17 | 2024-12-10 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물 |
| NZ738068A (en) | 2015-05-06 | 2019-07-26 | Snipr Tech Ltd | Altering microbial populations & modifying microbiota |
| EP3932428A1 (en) | 2015-05-21 | 2022-01-05 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| AU2016291817A1 (en) | 2015-07-16 | 2018-02-22 | Biolinerx Ltd. | Compositions and methods for treating cancer |
| CA3004138A1 (en) * | 2015-11-03 | 2017-05-11 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and tim-3 and their uses |
| CA3004530A1 (en) | 2015-11-07 | 2017-05-11 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| CN115350263A (zh) | 2016-05-20 | 2022-11-18 | 拜尔哈文制药股份有限公司 | 谷氨酸调节剂与免疫疗法用以治疗癌症的用途 |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| US20190233534A1 (en) | 2016-07-14 | 2019-08-01 | Fred Hutchinson Cancer Research Center | Multiple bi-specific binding domain constructs with different epitope binding to treat cancer |
| GB201616365D0 (en) * | 2016-09-27 | 2016-11-09 | Helsingin Yliopisto | Non-genetic modification of enveloped viruses |
| MX2019003447A (es) | 2016-09-27 | 2019-08-29 | Univ Texas | Metodos para mejorar la terapia de bloqueo del punto de control inmune mediante la modulacion del microbioma. |
| CN116672456A (zh) | 2016-10-12 | 2023-09-01 | 得克萨斯州大学系统董事会 | 用于tusc2免疫治疗的方法和组合物 |
| CA3037851A1 (en) | 2016-10-21 | 2018-04-26 | Innate Pharma | Treatment with anti-kir3dl2 agents |
| KR20190112263A (ko) | 2016-12-12 | 2019-10-04 | 멀티비르 인코포레이티드 | 암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물 |
| US20210101980A1 (en) | 2017-03-31 | 2021-04-08 | Bristol-Myers Squibb Company | Methods of treating tumor |
| AU2018248672B2 (en) | 2017-04-05 | 2021-09-30 | Korea Research Institute Of Bioscience And Biotechnology | NK cell-activating fusion protein, NK cell, and pharmaceutical composition including same |
| KR102376863B1 (ko) | 2017-05-12 | 2022-03-21 | 하푼 테라퓨틱스, 인크. | 메소텔린 결합 단백질 |
| WO2018218207A1 (en) | 2017-05-26 | 2018-11-29 | Fred Hutchinson Cancer Research Center | Anti-cd33 antibodies and uses thereof |
| CN107261304A (zh) * | 2017-06-05 | 2017-10-20 | 中国兽医药品监察所 | 一种奶牛的布鲁氏菌病免疫试剂盒及其应用 |
| SG11202000402PA (en) | 2017-08-10 | 2020-02-27 | Nat Univ Singapore | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| CN111630070B (zh) | 2017-10-13 | 2024-07-30 | 哈普恩治疗公司 | 三特异性蛋白质及使用方法 |
| WO2019075468A1 (en) | 2017-10-15 | 2019-04-18 | Bristol-Myers Squibb Company | TUMOR TREATMENT METHODS |
| CN108060137B (zh) * | 2017-12-26 | 2021-07-02 | 博生吉医药科技(苏州)有限公司 | Il7和il21修饰的nk92细胞、制备方法及其应用 |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| PE20210375A1 (es) | 2018-02-08 | 2021-03-02 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales |
| FI3749346T3 (fi) | 2018-02-08 | 2024-09-04 | Dragonfly Therapeutics Inc | Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät |
| MX2020008684A (es) | 2018-02-20 | 2020-12-07 | Dragonfly Therapeutics Inc | Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso. |
| US12454561B2 (en) | 2018-03-19 | 2025-10-28 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer |
| KR102761890B1 (ko) | 2018-03-23 | 2025-02-06 | 브리스톨-마이어스 스큅 컴퍼니 | Mica 및/또는 micb에 대한 항체 및 그의 용도 |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| JP7761995B2 (ja) | 2018-03-25 | 2025-10-29 | エスエヌアイピーアール・バイオーム・アーペーエス | 微生物感染症の治療及び予防 |
| JP2021519771A (ja) | 2018-03-30 | 2021-08-12 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 腫瘍を処置する方法 |
| AU2019275076B2 (en) | 2018-05-23 | 2024-12-19 | National University Of Singapore | Blockade of CD2 surface expression and expression of chimeric antigen receptors for immunotherapy of T-cell malignancies |
| US12384851B2 (en) | 2018-08-08 | 2025-08-12 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| JP7482363B2 (ja) | 2018-08-08 | 2024-05-14 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及び腫瘍関連抗原に結合するタンパク質 |
| EP3849565A4 (en) | 2018-09-12 | 2022-12-28 | Fred Hutchinson Cancer Research Center | REDUCTION OF CD33 EXPRESSION TO SELECTIVELY PROTECT THERAPEUTIC CELLS |
| WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
| US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| US20220054524A1 (en) | 2018-12-21 | 2022-02-24 | Onxeo | New conjugated nucleic acid molecules and their uses |
| JP2022534981A (ja) | 2019-05-30 | 2022-08-04 | ブリストル－マイヤーズ スクイブ カンパニー | 細胞局在化シグネチャーおよび組み合わせ治療 |
| CN114127315A (zh) | 2019-05-30 | 2022-03-01 | 百时美施贵宝公司 | 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法 |
| WO2020243563A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Multi-tumor gene signatures for suitability to immuno-oncology therapy |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| CN111424012A (zh) * | 2020-03-30 | 2020-07-17 | 威海市中心医院 | 一种nk细胞培养用的饲养细胞去增殖能力的处理方法 |
| TW202208428A (zh) | 2020-05-06 | 2022-03-01 | 美商蜻蜓醫療公司 | 結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質 |
| AR122644A1 (es) | 2020-06-19 | 2022-09-28 | Onxeo | Nuevas moléculas de ácido nucleico conjugado y sus usos |
| AU2021306613A1 (en) | 2020-07-07 | 2023-02-02 | BioNTech SE | Therapeutic RNA for HPV-positive cancer |
| MX2023002326A (es) | 2020-08-31 | 2023-03-21 | Bristol Myers Squibb Co | Firma de localizacion celular e inmunoterapia. |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| US20240000837A1 (en) * | 2020-12-23 | 2024-01-04 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Inhibition of kir2dl2 for the enhancement of adoptive immunotherapies |
| WO2022146948A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
| AU2021411486A1 (en) | 2020-12-28 | 2023-06-29 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| MX2023009100A (es) | 2021-02-03 | 2023-09-25 | Mozart Therapeutics Inc | Agentes aglutinantes y métodos para usar los mismos. |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| US20240376224A1 (en) | 2021-04-02 | 2024-11-14 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| CA3225254A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| MX2024004082A (es) | 2021-10-08 | 2024-04-18 | 3M Innovative Properties Company | Montaje de troquel de ranura con rigidez ajustada, zona de extraccion reducida y estimacion de fuerza. |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2023110937A1 (en) | 2021-12-14 | 2023-06-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling |
| IL313439A (en) | 2021-12-16 | 2024-08-01 | Valerio Therapeutics | New conjugated nucleic acid molecules and their uses |
| WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
| US20250332252A1 (en) | 2022-06-02 | 2025-10-30 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
| WO2024026385A1 (en) * | 2022-07-28 | 2024-02-01 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Inhibition of kir2dl2 and/or kir2dl3 for the enhancement of adoptive immunotherapies |
| TW202426486A (zh) * | 2022-10-25 | 2024-07-01 | 日商第一三共股份有限公司 | 使用針對抑制型ｋｉｒ的促效劑的免疫排斥之迴避方法 |
| KR20250120305A (ko) | 2022-12-14 | 2025-08-08 | 아스텔라스 파마 유럽 비.브이. | Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법 |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| CN117883553B (zh) * | 2024-01-12 | 2024-08-27 | 成都医学院 | Pml-1蛋白在制备抑制细胞因子风暴的药物中的应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| US5539094A (en) | 1993-11-12 | 1996-07-23 | La Jolla Cancer Research Foundation | DNA encoding Bcl-2-associated proteins |
| IL108501A (en) * | 1994-01-31 | 1998-10-30 | Mor Research Applic Ltd | Antibodies and pharmaceutical compositions containing them |
| US5583034A (en) | 1994-02-22 | 1996-12-10 | La Jolla Institute For Allergy And Immunology | Enhancement of adoptosis using antisense oligonucleotides |
| US5808028A (en) * | 1994-05-24 | 1998-09-15 | The United States Of America As Represented By The Department Of Health And Human Services | Molecular clone of a P58 receptor protein and uses thereof |
| NZ298145A (en) | 1994-12-29 | 1998-08-26 | Yamanouchi Pharma Co Ltd | Monoclonal antibodies having inhibitory effect on type ii phospholipase a2, proteins forming part thereof, cells producing them, dna encoding them, recombinant vector comprising the dna and medicament |
| US6750044B1 (en) | 1996-10-17 | 2004-06-15 | Genentech, Inc. | Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids |
| JP2002529705A (ja) * | 1998-10-29 | 2002-09-10 | コンネクス・ゲーエムベーハー | 糞便中の耐酸性微生物を検出するための新規方法 |
| CA2372053C (en) | 1999-04-28 | 2008-09-02 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
| KR100419555B1 (ko) * | 2000-05-29 | 2004-02-19 | 주식회사유한양행 | 비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자 |
| CA2532547C (en) * | 2003-07-24 | 2020-02-25 | Innate Pharma | Methods and compositions for increasing the efficiency of therapeutic antibodies using nk cell potentiating compounds |
| CA2601417C (en) | 2004-07-01 | 2018-10-30 | Novo Nordisk A/S | Human anti-kir antibodies |
| PT1831258E (pt) * | 2004-12-28 | 2016-01-07 | Univ Genova | Anticorpos monoclonais contra nkg2a |
| EP1836225B1 (en) * | 2005-01-06 | 2011-11-02 | Novo Nordisk A/S | Kir-binding agents and methods of use thereof |
| JP5154949B2 (ja) * | 2005-01-06 | 2013-02-27 | ノヴォ ノルディスク アー／エス | ウイルス感染を治療するための組成物および方法 |
| JP5855326B2 (ja) * | 2005-01-06 | 2016-02-09 | ノヴォ ノルディスク アー／エス | 抗ｋｉｒ組み合わせ治療および方法 |
| EP2322557B1 (en) * | 2005-10-14 | 2017-08-30 | Innate Pharma | Compositions and methods for treating proliferative disorders |
| EP2109460B1 (en) | 2007-01-11 | 2016-05-18 | Novo Nordisk A/S | Anti-kir antibodies, formulations, and uses thereof |
| AU2012260601B2 (en) * | 2011-05-25 | 2018-02-01 | Innate Pharma, S.A. | Anti-KIR antibodies for the treatment of inflammatory disorders |
| US9789182B2 (en) * | 2012-10-23 | 2017-10-17 | Bristol-Myers Squibb Company | Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer |
| WO2015069785A1 (en) * | 2013-11-06 | 2015-05-14 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma |
| US9884593B2 (en) * | 2015-02-12 | 2018-02-06 | Pro-Gard Products, Llc | Weapon mounting system |
-
2004
- 2004-07-01 ES ES04744115T patent/ES2393485T3/es not_active Expired - Lifetime
- 2004-07-01 CN CN201310057089.0A patent/CN103588880B/zh not_active Expired - Lifetime
- 2004-07-01 JP JP2006515738A patent/JP5015592B2/ja not_active Expired - Lifetime
- 2004-07-01 ES ES10178580T patent/ES2725526T3/es not_active Expired - Lifetime
- 2004-07-01 BR BRPI0412138A patent/BRPI0412138B8/pt not_active IP Right Cessation
- 2004-07-01 US US10/563,045 patent/US9902936B2/en active Active
- 2004-07-01 DK DK04744115.9T patent/DK1639013T3/da active
- 2004-07-01 CA CA2530272A patent/CA2530272C/en not_active Expired - Lifetime
- 2004-07-01 BR BRPI0412153A patent/BRPI0412153B8/pt not_active IP Right Cessation
- 2004-07-01 WO PCT/IB2004/002464 patent/WO2005003172A2/en not_active Ceased
- 2004-07-01 MX MXPA05013923A patent/MXPA05013923A/es active IP Right Grant
- 2004-07-01 AU AU2004253770A patent/AU2004253770C1/en not_active Expired
- 2004-07-01 AT AT04738967T patent/ATE490984T1/de not_active IP Right Cessation
- 2004-07-01 DE DE602004030464T patent/DE602004030464D1/de not_active Expired - Lifetime
- 2004-07-01 RU RU2005140152/13A patent/RU2376315C2/ru active
- 2004-07-01 EP EP10178580.6A patent/EP2289939B1/en not_active Expired - Lifetime
- 2004-07-01 CA CA002530591A patent/CA2530591A1/en not_active Abandoned
- 2004-07-01 KR KR1020137013482A patent/KR101444717B1/ko not_active Expired - Lifetime
- 2004-07-01 EP EP04738967A patent/EP1673397B1/en not_active Expired - Lifetime
- 2004-07-01 PT PT47441159T patent/PT1639013E/pt unknown
- 2004-07-01 HR HRP20120845TT patent/HRP20120845T1/hr unknown
- 2004-07-01 KR KR1020067000109A patent/KR101375153B1/ko not_active Expired - Lifetime
- 2004-07-01 AU AU2004253630A patent/AU2004253630B2/en not_active Expired
- 2004-07-01 KR KR1020127002275A patent/KR101325023B1/ko not_active Expired - Lifetime
- 2004-07-01 KR KR1020067000025A patent/KR20060079180A/ko not_active Ceased
- 2004-07-01 RU RU2006102960/10A patent/RU2404993C2/ru active
- 2004-07-01 CN CN201310392765.XA patent/CN103467602B/zh not_active Expired - Lifetime
- 2004-07-01 PL PL04744115T patent/PL1639013T3/pl unknown
- 2004-07-01 WO PCT/DK2004/000470 patent/WO2005003168A2/en not_active Ceased
- 2004-07-01 DK DK04738967.1T patent/DK1673397T3/da active
- 2004-07-01 JP JP2006516606A patent/JP4871125B2/ja not_active Expired - Lifetime
- 2004-07-01 KR KR1020127013323A patent/KR101420344B1/ko not_active Expired - Lifetime
- 2004-07-01 EP EP04744115A patent/EP1639013B1/en not_active Expired - Lifetime
-
2005
- 2005-12-15 IL IL172613A patent/IL172613A/en active IP Right Grant
- 2005-12-19 NO NO20056048A patent/NO338818B1/no unknown
- 2005-12-20 IL IL172700A patent/IL172700A/en active IP Right Grant
-
2006
- 2006-02-01 NO NO20060528A patent/NO338255B1/no unknown
-
2012
- 2012-04-06 JP JP2012087648A patent/JP5826697B2/ja not_active Expired - Lifetime
- 2012-11-28 CY CY20121101151T patent/CY1113394T1/el unknown
-
2015
- 2015-03-04 JP JP2015042824A patent/JP6556465B2/ja not_active Expired - Lifetime
- 2015-04-28 IL IL238490A patent/IL238490A0/en unknown
-
2016
- 2016-02-16 NO NO20160264A patent/NO342318B1/no unknown
- 2016-03-10 NO NO20160411A patent/NO343342B1/no unknown
-
2018
- 2018-01-22 US US15/876,839 patent/US11365393B2/en active Active
- 2018-04-16 JP JP2018078329A patent/JP2018153185A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012176953A5 (OSRAM) | ||
| JP2015163068A5 (OSRAM) | ||
| JP2013198490A5 (OSRAM) | ||
| EP4286415A3 (en) | Humanized antigen-binding domains against cd19 and methods of use | |
| JP2017048240A5 (OSRAM) | ||
| JP2017052784A5 (OSRAM) | ||
| JP2018516853A5 (OSRAM) | ||
| JP2018510636A5 (OSRAM) | ||
| WO2016207304A8 (en) | Monoclonal anti-il-1racp antibodies | |
| JP2017114866A5 (OSRAM) | ||
| CN110291109A (zh) | 人程序性死亡受体pd-1的单克隆抗体及其片段 | |
| JP2009225799A5 (OSRAM) | ||
| HRP20230411T1 (hr) | Dvostruko ciljanje | |
| JP2012502649A5 (OSRAM) | ||
| JP2012116856A5 (OSRAM) | ||
| JP2017149720A5 (OSRAM) | ||
| JP2017500057A5 (OSRAM) | ||
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| JP2013506428A5 (OSRAM) | ||
| JP2017504578A5 (OSRAM) | ||
| JP2016533763A5 (ja) | ヒトｐｄ−１に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物 | |
| MY188237A (en) | Anti-pd-l1 antibodies and uses thereof | |
| JP2015504421A5 (OSRAM) | ||
| RU2017134495A (ru) | Антитела к альфа-рецептору собачьего интерлейкина-4 | |
| NZ623706A (en) | Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof |